Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Los Bonos 1 (no aplicable en España), 2 (Marcas y Diseños) y 3 (patentes nacionales, patentes europeas, informes tecnológicos de patentes y búsquedas retrospectivas) se encuentran cerrados desde el 20/08/2025. La solicitud del Bono 4 sigue abierta. Más adelante se informará sobre la reapertura de estos Bonos
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
179
resultados
Última actualización
22/08/2025 [06:51:00]
Resumen de: EP4603589A2
The present disclosure includes cationic carrier units comprising (i) a water soluble polymer, (ii) a positively charged carrier, and (iii) an adjuvant moiety, wherein when the cationic carrier unit is mixed with an anionic payload (e.g., an antisense oligonucleotide) that electrostatically interacts with the cationic carrier unit, the resulting composition self-organizes into a micelle encapsulating the anionic payload in its core. The cationic carrier units can also comprise a tissue specific targeting moiety, which would be displayed on the surface of the micelle. The disclosure also includes micelles comprising the cationic carrier units of the disclosure, methods of manufacture of cationic carrier units and micelles, pharmaceutical compositions comprising the micelles, and also methods of treating diseases or conditions comprising administering the micelles to a subject in need thereof.
Resumen de: WO2024081668A2
Described herein are compounds comprising a lipid connected to a backbone of a polymer with functional groups. Also described herein is the use of such reagents for delivering nucleic acids to a cell.
Resumen de: WO2024079756A2
The invention relates to formulation for oral delivery of peptides and/or drug molecules and a method of manufacturing the same. The oral formulation is useful for delivering peptides to the gastrointestinal tract, preferably at the ileo-caecal junction of colon.
Resumen de: WO2024077376A1
Acute myeloid leukemia (AML) has not benefited from innovative immunotherapies, mainly because of the lack of actionable immune targets. Novel tumor-specific antigens (TSAs) shared by a large proportion of AML cells are described herein. Most of the TSAs described herein derives from aberrantly expressed unmutated genomic sequences, such as intronic and intergenic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells and vaccines derived from these TSAs are described. The use of the TSAs, nucleic acids, compositions, cells and vaccines for the treatment of myelodysplastic syndrome (MDS) or leukemia such as AML is also described.
Resumen de: AU2023361222A1
The present invention relates to pharmaceutical compositions comprising at least one lipid nanopartide (LNP) specific for targeting Langerhans cells (LC) wherein the LNP encapsulates at least one mRNA, is capable of specifically binding to the receptor Langerin and facilitates Langerin-mediated uptake and intracellular delivery of said mRNA molecule and its translation into at least one protein or peptide. Further envisaged is the pharmaceutical composition for use in the treatment of cancer, of an autoimmune disease, of a bacterial infection, of a viral infection, of a fungal infection or of a graft-vs. host disease, of a local or systemic inflammation, of an allergy, or for hyposensitization.
Resumen de: EP4603108A1
The present invention relates to a mannose-HSA based nanocarrier system, and a pharmaceutical composition containing the same for delivery of immunomodulatory drugs into target cells expressing surface mannose receptors. The present invention further relates to a method of manufacturing said mannoseHSA nanocarrier system.
Resumen de: WO2024095144A1
The present application relates to lipidic nanoparticles that are suitable for the treatment of neurologic or chronic diseases. The lipidic nanoparticles of the present application are of the solid lipid nanoparticles or nanostructured lipid carriers and comprise an encapsulated drug with a sustained and controlled drug delivery in the treatment of neurologic or chronic diseases.
Resumen de: MX2025004314A
The present invention relates to compounds of formula (I). The invention also extends to micro- or nanoparticles comprising a compound of formula (I). For instance, compounds of formula (I) can be used to produce stable lipid nanoparticles (LNPs). The LNPs have high encapsulation efficiency and can be used to deliver a therapeuticor prophylactic agent to a patient.
Resumen de: AU2023360051A1
The invention relates to oligonucleotides that inhibit Toll-Like Receptor 7 (TLR7) and/or Toll-Like Receptor 8 (TLR8), or potentiate TLR8, and uses thereof.
Resumen de: MX2022003239A
Disclosed herein are compositions and methods for treating a subject having cancer and other ferroptosis disorders with high density lipoprotein-like nanoparticles that induce ferroptosis.
Resumen de: MX2025005244A
The present invention provides delivery system compositions comprising self- assembling lipid nanoparticles for targeted delivery of therapeutic or diagnostic agents to target cells. The particles are non-covalently attached to a lipidated antibody or antibody fragment which comprises an antibody or antibody fragment attached, via a peptide linker, to a lipidated peptide portion, wherein the antibody or antibody fragment is at the distal end from the nanoparticle.
Resumen de: AU2023326249A1
The present disclosure relates to lipid nanoparticles for delivery of DNA, the lipid nanoparticle comprising therein a DNA-binding protein or peptide bound to the DNA, and uses thereof.
Resumen de: WO2024035783A2
Lipid nanoparticle compositions (LNPs), methods for preparing the LNPs, methods of using the same, including, but not limited to, for treatment of certain diseases and disorders, including, but not limited to liver disorders, kits for the delivery of nucleic acids to various types of cells, including T-cells and hepatocytes, in vivo, ex vivo and in vitro.
Resumen de: CN119816292A
Compounds, compositions, and methods for delivering therapeutic, diagnostic, or prophylactic agents (e.g., nucleic acids) are described.
Resumen de: AU2023321906A1
Provided herein are compositions and methods related to compositions comprising an Ig protease fusion protein. Also provided herein are compositions and methods for therapeutic treatment, such as of autoimmune diseases, allergies, or other immunological disorders, or in combination with the administration of another therapeutic, with such Ig protease fusion protein.
Resumen de: CN120478633A
本发明适用于生物医学技术领域，提供了一种三重协同调控的多功能复合纳米酶的制备方法，该方法构建了一种基于三重环境自适应调控机制的智能纳米酶体系AgAu C‑L。该体系通过AgAu纳米笼的光热效应精准优化催化反应温度，同时结合罗伊氏乳杆菌的益生菌代谢特性主动降低局部pH至CeO2最佳活性范围，并协同AgAu@CeO2异质结界面电子转移优化策略增强电荷传递效率，三者共同作用显著提升CeO2纳米酶在生理中性/弱碱性环境下的催化效能，特别是其过氧化物酶样活性。该智能体系不仅能高效物理清除牙周致病菌生物膜，更能通过精准干扰病原菌核苷酸合成与精氨酸代谢等关键通路瓦解微生物协同网络，最终实现口腔微生态平衡的重塑。
Resumen de: CN120478303A
本发明涉及一种双靶向仿生水滑石无机纳米颗粒及其制备方法和应用，包括：获取新鲜红细胞膜；获取衰老红细胞膜；将新鲜红细胞膜和衰老红细胞膜以一定的比例加入水滑石无机纳米颗粒中进行混合搅拌，离心得到仿生水滑石无机纳米颗粒。本发明的有益效果是：本发明双靶向仿生水滑石无机纳米颗粒具有平衡递送至肝实质细胞和肝巨噬细胞的双靶向能力，可同时缓解氧化应激和炎症反应。
Resumen de: CN120478306A
本发明适用于生物医学技术领域，提供了一种多功能纳米复合材料的制备方法及其应用。该材料生物相容性良好，可作为安全制剂用于肿瘤治疗；制备简便且绿色无污染；扩展了槲皮素在抗肿瘤免疫治疗中的应用；具有优异的荧光/计算机断层扫描双模式成像性能，可用于确定肿瘤边界，实现精准治疗引导；具有优良的光热及光热增强的催化性能，具备微创高效、毒副作用小且可控等优势，能通过激活免疫有效治疗原发、转移或复发性头颈部鳞状细胞癌；通过诱导肿瘤细胞释放2’3’‑cGAMP并防止其降解，高效激活cGAS‑STING信号通路，最终增强抗肿瘤免疫效果。
Resumen de: CN120478287A
本发明涉及纳米生物技术领域，提出了一种mRNA脂质纳米粒及其制备方法和应用。该mRNA脂质纳米粒，通过透明质酸酶（HAase）修饰以降解肿瘤细胞外基质中的透明质酸，改善肿瘤微环境，降低肿瘤组织的屏障作用，从而增强mRNA‑LNP的渗透性。此外，该体系在肿瘤微酸环境下可发生粒径翻转，提高肿瘤深层细胞的递送效率。实验结果表明，该递送体系可有效提高mRNA在肿瘤组织中的渗透能力和抗肿瘤疗效，为肿瘤基因治疗提供了一种新的策略。
Resumen de: CN120478304A
本发明涉及畜牧技术领域，尤其涉及一种呕吐毒素致断奶仔猪肠道铁死亡的抑制剂及制备方法，本发明整合铁螯合剂(去铁胺，DFO)、GPX4激活剂(硒甲硫氨酸，SeMet)及抗炎成分(姜黄素、黄芪多糖、双氢青蒿素)，覆盖铁蓄积、GPX4失活、脂质过氧化等铁死亡三大核心通路；同时，采用pH敏感型壳聚糖‑海藻酸钠纳米颗粒对以上成分进行包被，使其能够过胃，避免受到胃酸的破坏，确保药物在肠道的碱性环境中精准释放，从而提高药物的利用率；并且，硒甲硫氨酸、姜黄素、黄芪多糖、双氢青蒿素均为天然来源，可以避免化学药物残留风险，可作为饲料添加剂应用于断奶仔猪当中。
Resumen de: WO2024153108A1
The present invention discloses a chelating complex micelle presenting antimicrobial activity against gram-negative bacteria. The chelating complex micelle comprises metal ions, polymers having a chelating segment, and an antimicrobial agent having at least one Lewis base functional group, wherein the antimicrobial agent presenting antimicrobial activity against multi-drug-resistant gram-negative bacteria (MDR-GNB), such as carbapenem-resistant A. baumannii, P.aeruginosa, or Enterobacteriaceae.
Resumen de: CN120484249A
本发明属于生物医药技术领域，公开了一种含氟修饰的聚肌氨酸化脂质及其制备方法和应用。本发明的所述含氟修饰聚肌氨酸化脂质具有如式(I)或式(II)所示结构通式。通过不同含氟基团化学改性聚肌氨酸化脂质得到的含氟修饰聚肌氨酸化脂质可以替代PEG化脂质制备脂质纳米颗粒(LNP)，用于负载核酸等药物，达到提升药物递送性能的目的。
Resumen de: AU2023379457A1
The present invention provides, in part, protein-drug conjugates comprising an anti-fibroblast growth factor receptor 3 (FGFR3) (e.g., human FGFR3) antigen-binding protein (e.g., scFv, Fab) conjugated to a molecular cargo (e.g., polynucleotides, polypeptides, liposomes or lipid nanoparticles) for delivery of the molecular cargo to a targeted tissue (e.g., brain). Methods for treating various diseases or disorders, such as neurological diseases, with the conjugates are provided.
Resumen de: CN120478581A
本发明公开了基于冷萃酶解高温换能技术的骨筋粘膜多靶点复合制剂的制备方法，涉及医药技术领域。本发明包括以下步骤：步骤一：原料预处理：选用新鲜、无污染的鳕鱼皮和鹿筋作为主要原料，将鳕鱼皮洗净，去除表面的杂质和脂肪，切成边长约0.5‑1cm的小块，鹿筋用30‑40℃温水浸泡12‑15小时进行泡发。本发明通过独特的4‑15℃低温阶段、15‑37℃阶梯升温阶段和脉冲热处理，有效避免了传统热提取对胶原蛋白等热敏性成分的破坏，保留了原料的天然活性，在低温阶段，温和的酶解条件能使原料中的热敏性物质得以完整保留，脉冲热处理则使胶原肽构象转换率提高，显著提升了其生物利用度和活性，更利于人体吸收和利用。
Nº publicación: CN120478400A 15/08/2025
Solicitante:
上海市第六人民医院
Resumen de: CN120478400A
本发明提供了一种DACe@ET纳米药物的制备方法及其应用，制备方法，包括以下步骤：合成金纳米颗粒、金/二氧化铈核核壳结构纳米颗粒、修饰氨基聚乙二醇马来酰亚胺和星形胶质细胞归巢肽DAG；将星形胶质细胞归巢肽DAG和ET‑18‑OCH3加入金/二氧化铈核核壳结构纳米颗粒的溶液中，离心得到DACe@ET纳米药物；DACe@ET纳米药物在脑淀粉样血管病的治疗中的应用，能够调节氧化还原平衡和降低脑内铁沉积；本发明的DACe@ET纳米药物通过提高抗氧化能力，并改善细胞摄取能力，从而提高药物的生物利用度；可有效减少CAA模型小鼠脑内铁的异常积累，恢复脑内氧化还原平衡，表明其具有优异的脑铁稳态调控能力。
BOPI
Sede Electrónica
